Eric P Grewal

Featured in: Favicon

nature.com Favicon

futuremedicine.com

Articles

Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial - Nature Communications

Feb 16, 2024 | nature.com | Eric P Grewal |jun chen |Robert McWilliams |Robert Mcwilliams |Lu Yang |Evidio Domingo-Musibay | +5 more

AbstractBoth targeted therapies and immunotherapies provide benefit in resected Stage III melanoma. We hypothesized that the combination of targeted and immunotherapy given prior to therapeutic lymph node dissection (TLND) would be tolerable and drive robust pathologic responses.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →